In the phase 3 TOWER (NCT00751881) study, teriflunomide 14 mg significantly reduced annualized relapse rate (ARR) and risk of 12-week confirmed disability worsening (12-w CDW) vs placebo in patients with relapsing forms of MS (RMS). The TOWER population included an appreciable proportion of Asian patients. Reductions in ARR and 12-w CDW associated with teriflunomide 14 mg were comparable between the Asian and overall populations, as were the rates for adverse events and serious adverse events, with no new or unexpected safety findings. These observations provide further evidence to support the clinical benefits and safety profile of teriflunomide in a broad range of patients with RMS.
Introduction
Teriflunomide is a once-daily oral immunomodulator approved for the treatment of relapsing-remitting MS in 80 countries, and as of October 2017, over 80,000 patients are being treated with teriflunomide worldwide. TOWER (NCT00751881 [1] ) was a phase 3 trial of teriflunomide in patients with relapsing forms of MS (RMS) conducted in 26 countries. The primary endpoint was the annualized relapse rate (ARR) and the key secondary endpoint was the risk of 12-week confirmed disability worsening (12-w CDW). The efficacy of teriflunomide on ARR and disability progression were consistent in prespecified subgroup analyses in which patients were stratified by demographics, including ethnicity, and baseline disease characteristics [2] . In TEMSO (NCT00134563 [3] ), another phase 3 study in patients with RMS, the positive clinical effects of teriflunomide were also demonstrated consistently across subgroups defined by demographics and baseline disease characteristics [4] . This report summarizes efficacy and safety outcomes in a subgroup of Asian patients enrolled in TOWER.
Methods
TOWER was a randomized, double-blind, placebo-controlled trial, and the study design has been previously reported [1] . Briefly, patients with RMS were randomized 1:1:1 to receive placebo or teriflunomide 7 mg or 14 mg. TOWER adopted a variable treatment duration (48-173 weeks; median 83 weeks), with the study ending 48 weeks after the last patient was randomized. As the 14-mg dose of teriflunomide is the only dose currently approved in all countries other than the United States, data presented here focus on outcomes in the placebo and 14-mg groups. Race was selfidentified by patients, and this information was reported by the investigator.
TOWER was conducted in accordance with the International Conference on Harmonisation Guidelines for Good Clinical Practice [5] and the Declaration of Helsinki [6] . Study protocols were approved by central and local ethics committees and each site's Institutional Review Board. All patients gave written consent prior to participation.
Results
Of the 1165 patients included in the intent-to-treat TOWER population, 168 (14.4%) were either Asian or of Asian descent. Demographic and baseline disease characteristics of this subgroup were comparable to the overall population, except that Asian patients had a shorter time since first symptoms of MS and fewer Asian patients had received another disease-modifying therapy (DMT) within the last 2 years (Table 1) .
Teriflunomide 14 mg significantly reduced ARR by 66.8% (P = 0.0015) and 36.3% (P = 0.0001) vs placebo in the Asian (Fig. 1A) and overall populations, respectively. Teriflunomide 14 mg reduced the risk of 12-w CDW vs placebo by 49.2% (P = 0.3172) within the Asian subgroup, reflecting the trend observed in the overall population (31.5%, P = 0.0442), although the difference was not statistically significant owing to lack of power with the small sample size (Fig. 1B) .
The incidence of adverse events (AEs) in the Asian population was comparable across treatment groups (Table 2 ) and similar to that observed in the overall TOWER population [1] . Overall, the incidence of serious AEs was consistent among all of the treatment groups in both populations, and AEs leading to permanent treatment discontinuation occurred in 16.1% of the Asian population and 11.6% of the overall population. Four deaths occurred in TOWER, of which 3 were reported in the Asian subpopulation (placebo, respiratory infection; teriflunomide 14 mg, suicide and septicemia); none was considered drug-related [1] .
Discussion
This analysis of the Asian population enrolled in the TOWER study demonstrated comparable efficacy and safety outcomes to those of the overall population. Demographics and baseline disease characteristics were broadly similar between the populations, with the exceptions of a shorter time since first symptoms of MS and fewer previous DMTs reported for Asian patients. The incidence of AEs and serious AEs in the Asian subgroup was comparable between the treatment groups, with no new or unexpected safety findings compared to those demonstrated in the overall TOWER study. In both populations, the discontinuation of treatment because of AEs was more frequent in the teriflunomide treatment groups compared with placebo, mainly owing to a protocoldefined requirement to discontinue treatment in the event of increased alanine aminotransferase or decreased neutrophils. These data provide further evidence in support of the safety profile and clinical benefits of teriflunomide in a diverse ethnic population of patients with RMS.
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